Trials / Withdrawn
WithdrawnNCT02212613
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
Protocol 331-13-004: An Exploratory, Multicenter, Single-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC 34712) (2 mg/Day Tablets) as an Adjunctive Treatment
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexpiprazole | Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2014-08-08
- Last updated
- 2016-07-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02212613. Inclusion in this directory is not an endorsement.